<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>1(k)Application illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 003. Revision 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>June 21, 2010</td></tr></table>

# JUL 0 9 2010

# 510(k) number:

K100818

Submitter: Submitter's address:

# Meridian Bioscience, Inc.

3471 River Hills Drive Cincinnati, Ohio 45244 Michelle Smith (513) 271-3700

Contact: Contact number:

Device name:

illumigene ™ C. difficile   
illumipro- $1 0 ^ { \mathfrak { r m } }$ Automated Isothermal Amplification and Detection System   
illumigene ™ C. difficile External Control Kit

Common name: Classification name:

C. difficile DNA Amplification Assay C. difficile Nucleic Acids OMN, CFR Section 866.2660

# Predicate device:

K091109: Cepheid® Xpert@ C. difficile   
Model GXVDIFFICILE-10,900-0423, 900-0065, 900-0144, 900-0145, 900-0146,   
9000381, 900-0391, 900-0392, 900-393, 950-0151

# Reference comparator:

Cytotoxic bacterial culture

# Description of the device:

h loa silit thllixtelonolnhlealliitD Sysm.Thele iffici A mlificatissyi ooiatohealpatio LAMP fl RBolt phpColl ru llollpus r extracted in the Extraction Tube and DNA amplification occurs in the illumigene C.difficile Test Device.

Tl Magnesim pyrophosphate is formed.Magnesium pyrophosphate orms a precipitate in the reaction mixtur.The oshap suo  segaivashann

Teltl  oio Exat Kit is required for routine Quality Control.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>510(k) Application ilumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 003. Revision 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>June 21, 2010</td></tr></table>

# Intended Use:

Tecocit(CDAD).

ly all known $A + B +$ and $\mathsf { A } { \mathsf { - B } } { \mathsf { + } }$ toxinotypes.

ise.

# Comparison to predicated device:

<table><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Illumigene™ C. difficile</td><td colspan="1" rowspan="1">Cepheid® Xpert® C. difficile</td></tr><tr><td colspan="1" rowspan="1">Test Format</td><td colspan="1" rowspan="1">DNA Amplification Assay</td><td colspan="1" rowspan="1">DNA Amplification Assay</td></tr><tr><td colspan="3" rowspan="1">Intended Use</td></tr><tr><td colspan="1" rowspan="1">DNA Amplification Technology</td><td colspan="1" rowspan="1">Loop-Mediated Isothermal Amplification (LAMP)</td><td colspan="1" rowspan="1">Real-Time Polymerase Chain Reaction (PCR)</td></tr><tr><td colspan="1" rowspan="1">Target Sequences Detected</td><td colspan="1" rowspan="1">Partial DNA fragment on the Toxin A gene of thepathogenicity locus (PaLoc) found in all knownstrains for toxigenic C. difficile.</td><td colspan="1" rowspan="1">Toxin B sequences</td></tr><tr><td colspan="1" rowspan="1">Qualitative/Quantitative</td><td colspan="1" rowspan="1">Qualitative</td><td colspan="1" rowspan="1">Qualitative</td></tr><tr><td colspan="1" rowspan="1">Screening, Diagnostic orIdentification Test</td><td colspan="1" rowspan="1">Diagnostic</td><td colspan="1" rowspan="1">Diagnostic</td></tr><tr><td colspan="3" rowspan="1">Specimen Types</td></tr><tr><td colspan="1" rowspan="1">Unformed Human Stool</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">Yes</td></tr><tr><td colspan="1" rowspan="1">Human Stool in Cary-Blair-basedMedia</td><td colspan="1" rowspan="1">Yes</td><td colspan="1" rowspan="1">No</td></tr><tr><td colspan="1" rowspan="1">Reagents/Components</td><td colspan="1" rowspan="1">illumigene Sample Preparation Apparatusillumigene Reaction Bufferillumigene C. difficile Assay Deviceillumigene Extraction TubesSample Collection Brushes</td><td colspan="1" rowspan="1">Xpert C. difficile Assay cartridgesSample ReagentReagent 1Reagent 2</td></tr><tr><td colspan="1" rowspan="1">Extraction</td><td colspan="1" rowspan="1">Manual</td><td colspan="1" rowspan="1">Self-contained and automated</td></tr><tr><td colspan="1" rowspan="1">Amplification</td><td colspan="1" rowspan="1">Self-contained and automated</td><td colspan="1" rowspan="1">Self-contained and automated</td></tr><tr><td colspan="1" rowspan="1">Detection</td><td colspan="1" rowspan="1">Self-contained and automated</td><td colspan="1" rowspan="1">Self-contained and automated</td></tr><tr><td colspan="1" rowspan="1">Testing Time</td><td colspan="1" rowspan="1">Approximately 60 minutes</td><td colspan="1" rowspan="1">Approximately 45 minutes</td></tr><tr><td rowspan="3">Meridian</td><td colspan="2">510(k) Application illumigene C. difficile</td></tr><tr><td>Description:</td><td>510(k) Summary illumigene C. difficile</td></tr><tr><td>Identification:</td><td>Attachment 003. Revision 002</td></tr><tr><td>Bioscience, Inc.</td><td>Date:</td><td>June 21, 2010</td></tr></table>

<table><tr><td colspan="1" rowspan="1">Calibration</td><td colspan="1" rowspan="1">Not required</td><td colspan="1" rowspan="1">Not required</td></tr><tr><td colspan="3" rowspan="1">Comparison to predicated device:</td></tr><tr><td colspan="1" rowspan="1">Characteristic</td><td colspan="1" rowspan="1">Illumigene ™ C. difficile</td><td colspan="1" rowspan="1">Cepheid® Xpert® C. difficile</td></tr><tr><td colspan="3" rowspan="1">Controls</td></tr><tr><td colspan="1" rowspan="1">Inhibition, Assay</td><td colspan="1" rowspan="1">Providedillumigene Sample Preparation Apparatus:Staphylococcus aureusillumigene C. difficile Assay Device:Staphylococcus aureus LAMP Primers</td><td colspan="1" rowspan="1">ProvidedSample Processing Control (SPC): Bacillus globigiiProbe Check Control (PCC): Fluorescence emittingprobes</td></tr><tr><td colspan="1" rowspan="1">External</td><td colspan="1" rowspan="1">Adjunct Reagentsillumigene C. difficile External Control KitCatalog 279920</td><td colspan="1" rowspan="1">User SuppliedKWIK-STIK™M from MicroBioLogics catalog 0329toxigenic C. difficile) as positive controlKWIK-STIK™ from MicroBioLogics catalog 0331 (C.sordelli) as negative control</td></tr><tr><td colspan="1" rowspan="1">Extraction</td><td colspan="1" rowspan="1">User Supplied</td><td colspan="1" rowspan="1">User Supplied</td></tr><tr><td colspan="3" rowspan="1">Equipment</td></tr><tr><td colspan="1" rowspan="1">Instrumentation</td><td colspan="1" rowspan="1">illumipro-10™ Automated IsothermalAmplification and Detection System</td><td colspan="1" rowspan="1">GeneXpert® Dx System</td></tr><tr><td colspan="1" rowspan="1">General Laboratory Equipment</td><td colspan="1" rowspan="1">Micropipette 50 μL, 200 μLDry-bath with 12mm heat block, 95 CInterval TimerVortex Mixer</td><td colspan="1" rowspan="1">Vortex Mixer</td></tr><tr><td colspan="1" rowspan="1">Reading Method</td><td colspan="1" rowspan="1">Visible Light Transmission</td><td colspan="1" rowspan="1">Fluorescence</td></tr><tr><td colspan="3" rowspan="1">Results</td></tr><tr><td colspan="1" rowspan="1">C. difficile ToxinotypesTested</td><td colspan="1" rowspan="1">0A+/B+1lI (A+/B+)V(A+/B+)VII (A-/B+)X(A-/B+)XII (A+/B+)IXIXXIII (A+/B+)</td><td colspan="1" rowspan="1">0(A+/B+)II (A+/B+)V (A+/B+)VII (A-/B+)XII (A+/B+)</td></tr><tr><td colspan="1" rowspan="1">Results Interpretation</td><td colspan="1" rowspan="1">INVAIDPOSITIVENEGATIVE</td><td colspan="1" rowspan="1">Toxigenic C. difficile POSITIVEToxigenic C. difficile NEGATIVEINVALIDERRORNO RESULT</td></tr><tr><td rowspan="2">Meridian</td><td colspan="2">510(k) Application illumigene C. difficile</td></tr><tr><td>Description:</td><td>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan="2">Bioscience, Inc.</td><td>Identification:</td><td>Attachment 003. Revision 002</td></tr><tr><td>Date:</td><td>June 21, 2010</td></tr></table>

# Performance Comparison, Non-clinical Tests:

# Interference Testing

Sel ugnheron-icobal ubstans hat might be presnt  tol smps fmheay per pii pleeatalgativencnti psitiv s we edor ples  wc iuii this organism. Potentially interfering substances were added at final concentrations of $5 \%$ V/V or greater. Dilution C  ple  phuffeolupy interfering substance. Each sample was tested in triplicate.

Too difficile test results in the final concentrations listed: Barium sulfate $\{ 5 \ : \mathrm { m g / m L } \}$ , fecal fat (equivalent to $2 . 6 5 ~ \mathsf { m g }$ stearic plus 1.3 mg palmitic acids per mL), hemoglobin (as methemoglobin) $( 3 . 2 m g / m L )$ , IgA $( 5 \ m g / \ m L )$ , Imodium $\mathsf { A D @ }$ (0.00667 mg/mL), Kaopectate® $( 0 . 8 7 ~ \mathrm { m g / m L } )$ ,Metronidazole $( 1 2 . 5 \ m g / m L )$ , mucin $( 3 . 3 3 ~ \mathrm { m g / m L } )$ Mylanta $\textsuperscript { \textregistered }$ $( 4 . 2 \ m g / \ m L$ , PeptoBismo $1 \textcircled{8}$ EMPY $( 0 . 8 7 \ m g / m L )$ Prilosec $( 0 . 5 \mathrm { m g } / \mathrm { m L } )$ , Tagamet $( 0 . 5 \ m g / \ m L )$ , TUMS $\otimes$ $( 0 . 5 \mathrm { m g / m L } )$ , Vancomycin $( 1 2 . 5 \ m g / \ m L )$ , white blood cells (5%V/V), whole blood $5 \%$ VIV).

# Cross-reactivity Study

Potially coss-eactivmicorganis hat miht preent nsol smps oheay persos atnts i alivi osti cui i ii tr  U/t bov heFU sy organism. Potentially cross-reactive microorganisms were added at concentrations of $1 . 2 \times 1 0 ^ { 8 } / m L$ (bacteria and fungi) or $1 \times 1 0 ^ { 5 . 2 9 } / \mathrm { { m L } \ T C / \dot { D _ { 5 0 } } / \mathrm { { m L } } }$ (vues). Dilution Controls or each sample were prepared by addinga phosphate-buffered aoutin pe pncsacivni mp ws

T AerashydohBacoiesagisCmybacyacerusacereun ne, Lcs acListoncgenes Petosteptoocuanaobis,Pesoashigele, ulgisa sSeGos-Seru, SeratiaarsShiellabyShigellaeShigellasonSp urus,taphcus midsV prhaolyticusYerteocoliticaAenoisyCoxakivis , Rotavirus.

# Performance Comparison, Clinical Tests:

Cal detetn system, w cndctd in0. Pefoance charters theillgneCdiffl asy w SniSvalual t p were collected from 274 $\{ 3 9 . 3 \% \}$ males and 419 $( 6 0 . 1 \% )$ females. In the case of 4 $\{ 0 . 6 \% \}$ of the patients, sex was not kwn.Teoups attre oyr yars. oi observed based on patient age, sex, or geographical location. Overall Sensitivity was determined to be $9 5 . 2 \%$ $( 9 5 \%$ CI: $8 9 . 2 \% - 9 7 . 9 \%$ . Overall Specificity was determined to be $9 5 . 3 \%$ $( 9 5 \%$ CI: $9 3 . 2 \% - 9 6 . 7 \%$ . Subsequent tables show overall assay performance as well as performance by clinical site and patient age.

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>510(k) Application illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 003. Revision 002</td></tr><tr><td rowspan=1 colspan=1>Date:     :</td><td rowspan=1 colspan=1>June 21, 2010</td></tr></table>

Table 1. Overall performance data   

<table><tr><td rowspan=2 colspan=1>Cytotoxic bacterialculture</td><td rowspan=1 colspan=2>illumigene C. difficile</td><td rowspan=1 colspan=1></td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>Total</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>99</td><td rowspan=1 colspan=1>5**</td><td rowspan=1 colspan=1>104</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>27*</td><td rowspan=1 colspan=1>546</td><td rowspan=1 colspan=1>573</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>126</td><td rowspan=1 colspan=1>551</td><td rowspan=1 colspan=1>677</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Sensitivity</td><td rowspan=1 colspan=1>99/104</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>89.2 - 97.9%</td></tr><tr><td rowspan=1 colspan=1>Specificity</td><td rowspan=1 colspan=1>546/573</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=1>93.2 - 96.7%</td></tr><tr><td rowspan=1 colspan=1>Correlation</td><td rowspan=1 colspan=1>645/677</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=1>93.4 - 96.6%</td></tr></table>

FDA cleared assay for the detection of GDH. \*2/5 false negative results were negative by another FDA cleared molecular assay

Table 2. Performance characteristics by site   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigenelCytotoxicbacterialculture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenelCytotoxicbacterialculture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>99/104</td><td rowspan=1 colspan=1>95.2%</td><td rowspan=1 colspan=1>89.2 - 97.9%</td><td rowspan=1 colspan=1>546/573</td><td rowspan=1 colspan=1>95.3%</td><td rowspan=1 colspan=1>93.2 - 96.7%</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>4/5</td><td rowspan=1 colspan=1>80.0%</td><td rowspan=1 colspan=1>37.6-96.4%</td><td rowspan=1 colspan=1>58/60</td><td rowspan=1 colspan=1>97.6%</td><td rowspan=1 colspan=1>88.6 - 99.1%</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>12/12</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>75.7-100%</td><td rowspan=1 colspan=1>62/67</td><td rowspan=1 colspan=1>92.5%</td><td rowspan=1 colspan=1>83.7 -96.8%</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>83.9- 100%</td><td rowspan=1 colspan=1>87/92</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>87.9-97.7%</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>8/8</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>67.6 - 100%</td><td rowspan=1 colspan=1>36/39</td><td rowspan=1 colspan=1>92.3%</td><td rowspan=1 colspan=1>79.7 -97.3%</td></tr><tr><td rowspan=1 colspan=1>Site 5</td><td rowspan=1 colspan=1>55/59</td><td rowspan=1 colspan=1>93.2%</td><td rowspan=1 colspan=1>83.8-97.3%</td><td rowspan=1 colspan=1>303/315</td><td rowspan=1 colspan=1>96.2%</td><td rowspan=1 colspan=1>93.5-97.8%</td></tr></table>

Table 3. Invalid rates by site   

<table><tr><td rowspan=2 colspan=1>Site</td><td rowspan=1 colspan=4>Clinical Site Evaluation</td></tr><tr><td rowspan=1 colspan=1>Total Invalids</td><td rowspan=1 colspan=1>Assayinvalids</td><td rowspan=1 colspan=1>InstrumentInvalids</td><td rowspan=1 colspan=1>Invalid Rate</td></tr><tr><td rowspan=1 colspan=1>Site 1</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>3</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>3/68 (4.4%)</td></tr><tr><td rowspan=1 colspan=1>Site 2</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1/80 (1.3%)</td></tr><tr><td rowspan=1 colspan=1>Site 3</td><td rowspan=1 colspan=1>8</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>8/120 (6.7%)</td></tr><tr><td rowspan=1 colspan=1>Site 4</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>1/48 (2.1%)</td></tr><tr><td rowspan=1 colspan=1>Site 5</td><td rowspan=1 colspan=1>7</td><td rowspan=1 colspan=1>6</td><td rowspan=1 colspan=1>1</td><td rowspan=1 colspan=1>7/381 (1.8%)</td></tr><tr><td rowspan=1 colspan=1>Total</td><td rowspan=1 colspan=1>20</td><td rowspan=1 colspan=1>11/697 (1.6%)***</td><td rowspan=1 colspan=1>9/697 (1.3%)</td><td rowspan=1 colspan=1>20/697 (2.9%)</td></tr></table>

\*\*\* 1 Specimen remained invalid after repeat testing from the original sample.

Table 4. Results by patient age   

<table><tr><td rowspan=2 colspan=1>Patient age</td><td rowspan=1 colspan=3>Positive Samples</td><td rowspan=1 colspan=3>Negative Samples</td></tr><tr><td rowspan=1 colspan=1>illumigenelToxigenicculture</td><td rowspan=1 colspan=1>Sensitivity %</td><td rowspan=1 colspan=1>95% CI</td><td rowspan=1 colspan=1>illumigenelToxigenicculture</td><td rowspan=1 colspan=1>Specificity %</td><td rowspan=1 colspan=1>95% CI</td></tr><tr><td rowspan=1 colspan=1>≥ 2 -12 years</td><td rowspan=1 colspan=1>10/11</td><td rowspan=1 colspan=1>90.9%</td><td rowspan=1 colspan=1>62.3-98.4%</td><td rowspan=1 colspan=1>75/79</td><td rowspan=1 colspan=1>94.9%</td><td rowspan=1 colspan=1>87.7-98.0%</td></tr><tr><td rowspan=1 colspan=1>&gt; 12 to 21 years</td><td rowspan=1 colspan=1>5/5</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>56.6 - 100%</td><td rowspan=1 colspan=1>53/56</td><td rowspan=1 colspan=1>94.6%</td><td rowspan=1 colspan=1>85.4 - 98.2%</td></tr><tr><td rowspan=1 colspan=1>&gt; 21 years</td><td rowspan=1 colspan=1>83/87</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>88.8 - 98.2%</td><td rowspan=1 colspan=1>417/437</td><td rowspan=1 colspan=1>95.4%</td><td rowspan=1 colspan=1>93.0 -97.0%</td></tr><tr><td rowspan=1 colspan=1>Age Unknown</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20.7 - 100%</td><td rowspan=1 colspan=1>1/1</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20.7-100%</td></tr></table>

<table><tr><td rowspan=4 colspan=2>MeridianBioscience, Inc.</td><td rowspan=1 colspan=2>510(k) Application illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1>Description:</td><td rowspan=1 colspan=1>510(k) Summary illumigene C. difficile</td></tr><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=1>Identification:</td><td rowspan=1 colspan=1>Attachment 003. Revision 002</td></tr><tr><td rowspan=1 colspan=1>Date:</td><td rowspan=1 colspan=1>June 21, 2010</td></tr></table>

# Analytical Sensitivity

T probability (e.g., $9 5 \%$ or 19/20 positive replicates) of obtaining positive responses at the following levels of the measurands:

<table><tr><td rowspan=1 colspan=1>Strain ID</td><td rowspan=1 colspan=1>Toxinotype</td><td rowspan=1 colspan=1>Phenotype</td><td rowspan=1 colspan=1>LoD/Test</td></tr><tr><td rowspan=1 colspan=1>VPI 10463</td><td rowspan=1 colspan=1>0</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>4 CFU/test</td></tr><tr><td rowspan=1 colspan=1>2007431</td><td rowspan=1 colspan=1>III (NAP1)</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32 CFU/test</td></tr><tr><td rowspan=1 colspan=1>CF1</td><td rowspan=1 colspan=1>VIII</td><td rowspan=1 colspan=1>A-/B+</td><td rowspan=1 colspan=1>64CFU/test</td></tr><tr><td rowspan=1 colspan=1>2006240</td><td rowspan=1 colspan=1>V (NAP7)</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32CFU/test</td></tr><tr><td rowspan=1 colspan=1>BI8</td><td rowspan=1 colspan=1>III</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>64CFU/test</td></tr><tr><td rowspan=1 colspan=1>2007858</td><td rowspan=1 colspan=1>IX/XXIII</td><td rowspan=1 colspan=1>A+/B+</td><td rowspan=1 colspan=1>32CFU/test</td></tr><tr><td rowspan=1 colspan=1>8864</td><td rowspan=1 colspan=1>X</td><td rowspan=1 colspan=1>A-/B+</td><td rowspan=1 colspan=1>64 CFU/test</td></tr></table>

illuigene C.diffil.Strains and toxiotypes tested were as follows:Type0Strains:10463, 2004111, 0020, 2005070, 2005257, 2008029, 2008162, 2008341, 2008351, 2009066, 2009099, B1, G1, J7, K12, Y1; Type I Strains: 202, 2004118, 2007431, BI17, Bl8; Type V Strains:2005325, 2006240, 2008188, 2009018, 2009065, BK6 Type VIlI Strains: 43598, 2008016, CF1; Type $\pmb { \chi }$ Strains: 8864; Type XIi Strains: 2007435; Type IX/XXIl Strains: 2007858; Unknown Strains: 2009132, 2009155, 2009277.

# Reproducibility

Bcp ls eln   spl scicu assay limit of detection $( n = 3 )$ and just below the limit of blank (i.e., high negative sample, $\mathsf { n } = \mathsf { 3 }$ ). The panels also included uncharacterized positive $( n = 2 )$ and negative $( n = 2 )$ samples. Testing was performed by different operators at were used in this study. The results are given in the table below:

<table><tr><td rowspan=1 colspan=1></td><td rowspan=1 colspan=2>Site 1</td><td rowspan=1 colspan=2>Site 2</td><td rowspan=1 colspan=2>Site 3</td><td rowspan=1 colspan=2>Total</td></tr><tr><td rowspan=1 colspan=1>Sample Type</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td><td rowspan=1 colspan=2>Percent agreement</td></tr><tr><td rowspan=1 colspan=1>Negative</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>19/19****</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>59/59</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>High Negative</td><td rowspan=1 colspan=1>25/30</td><td rowspan=1 colspan=1>83%</td><td rowspan=1 colspan=1>29/30</td><td rowspan=1 colspan=1>97%</td><td rowspan=1 colspan=1>28/30</td><td rowspan=1 colspan=1>93%</td><td rowspan=1 colspan=1>82/90</td><td rowspan=1 colspan=1>91%</td></tr><tr><td rowspan=1 colspan=1>Low Positive</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>30/30</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>90/90</td><td rowspan=1 colspan=1>100%</td></tr><tr><td rowspan=1 colspan=1>Positive</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>20/20</td><td rowspan=1 colspan=1>100%</td><td rowspan=1 colspan=1>60/60</td><td rowspan=1 colspan=1>100%</td></tr></table>

\*\*\* 1 specimen generated an instrument invalid test result.

# Conclusions

Tl 1uman stool samples. The test is diagnostic for toxigenic C. difficile infection.

Meridian Bioscience, Inc. c/o Michelle L. Smith Senior Director, Quality Systems 3471 River Hills Dr. Cincinnati, OH 45244

Re: K100818 Trade/Device Name: Illumigene C. difficile Assay Regulation Number: 21 CFR $\ S 8 6 6 . 2 6 6 0$ Regulation Name: Microorganism differentiation and identification device Regulatory Class: Class I Product Code: OMN Dated: June 21, 2010 Received: June 22, 2010

Dear Ms. Smith:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class II (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to   
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/ResourcesforYou/Industry/default.htm.

Sincerely yours,

![](images/cfe35ff6a3d4c19813b2ac0309a59b79b4c7213628e14ab01e1d7c3ba27b37c3.jpg)

Sally A. Hojvat, M.Sc., Ph.D.   
Director   
Division of Microbiology Devices   
Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health

# Indication(s) for Use Form

510(k) Number (if known): K100818

Device Name: illumigene Molecular Diagnostic Test System (illumigene C. difficile DNA Amplification Assay, illumipro-10)

# Indications for Use:

T associated disease (CDAD).

Th l lA as an intact region remaining in all known $\ A + \ B +$ and $\scriptstyle \mathsf { A } \displaystyle \cdot \mathsf { B } +$ toxinotypes.

intended for point-of-care use.

Prescription Use___ Over-The-Counter Use (Part 21 CFR 801 Subpart D) AND/OR . (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

![](images/e1c83e90ea803e90a4e526a49080c3d53c9dd1a5fba08b6ef701937098a3539e.jpg)

Division Sign-Off   
Office of In Vitro Diagnostic Device   
Evaluation and Safety

510(k) K10 0818